U.S. Senate · 118th Congress · S. 142

Preserve Access to Affordable Generics and Biosimilars Act

A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products.

Sponsor

Amy KlobucharD-MN

Introduced

January 30, 2023, in the Senate

Issue areas

• Healthcare

Policy area

Health (from the Congressional Research Service)

Full text and actions

congress.gov